JP2022534118A5 - - Google Patents
Info
- Publication number
- JP2022534118A5 JP2022534118A5 JP2021570824A JP2021570824A JP2022534118A5 JP 2022534118 A5 JP2022534118 A5 JP 2022534118A5 JP 2021570824 A JP2021570824 A JP 2021570824A JP 2021570824 A JP2021570824 A JP 2021570824A JP 2022534118 A5 JP2022534118 A5 JP 2022534118A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962855277P | 2019-05-31 | 2019-05-31 | |
| US62/855,277 | 2019-05-31 | ||
| US201962906194P | 2019-09-26 | 2019-09-26 | |
| US62/906,194 | 2019-09-26 | ||
| PCT/US2020/035140 WO2020243442A1 (en) | 2019-05-31 | 2020-05-29 | Methods of treating urinary system cancers |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022534118A JP2022534118A (ja) | 2022-07-27 |
| JP2022534118A5 true JP2022534118A5 (https=) | 2023-05-19 |
| JPWO2020243442A5 JPWO2020243442A5 (https=) | 2023-05-19 |
Family
ID=73553913
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021570824A Pending JP2022534118A (ja) | 2019-05-31 | 2020-05-29 | 泌尿器系がんを治療する方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220233537A1 (https=) |
| EP (1) | EP3976833A4 (https=) |
| JP (1) | JP2022534118A (https=) |
| KR (1) | KR20220088830A (https=) |
| CN (1) | CN114207151A (https=) |
| AU (1) | AU2020282816A1 (https=) |
| CA (1) | CA3141871A1 (https=) |
| IL (1) | IL288408A (https=) |
| MX (1) | MX2021014524A (https=) |
| PH (1) | PH12021552973A1 (https=) |
| SG (1) | SG11202112932QA (https=) |
| WO (1) | WO2020243442A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3202267A1 (en) * | 2020-12-18 | 2022-06-23 | Riccardo Panicucci | Methods of treating achondroplasia |
| CN117982507A (zh) * | 2022-11-01 | 2024-05-07 | Qed医药股份有限公司 | 英菲格拉替尼在治疗胃癌和腺癌中的用途 |
| CN115785001B (zh) * | 2022-11-23 | 2023-09-15 | 斯坦德药典标准物质研发(湖北)有限公司 | 一种英菲格拉替尼的制备方法 |
| CN117558346B (zh) * | 2023-09-01 | 2024-12-03 | 上海仁东医学检验所有限公司 | Utuc分子分型及预后预测模型构建方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009523410A (ja) * | 2005-12-08 | 2009-06-25 | ノバルティス アクチエンゲゼルシャフト | 遺伝子転写に対するｆｇｆｒ３の阻害剤の効果 |
| EP2945652B1 (en) * | 2013-01-18 | 2021-07-07 | Foundation Medicine, Inc. | Methods of treating cholangiocarcinoma |
| TWI541022B (zh) * | 2013-12-18 | 2016-07-11 | 應克隆公司 | 針對纖維母細胞生長因子受體－３（ｆｇｆｒ３）之化合物及治療方法 |
| CN103757026B (zh) * | 2013-12-20 | 2017-04-05 | 广州圣露生物技术有限公司 | FGFR2b胞外段的基因序列、多肽及其应用 |
| EP4063516A1 (en) * | 2014-09-26 | 2022-09-28 | Janssen Pharmaceutica NV | Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor |
| SG11201906249PA (en) * | 2017-02-06 | 2019-08-27 | Rainier Therapeutics Inc | Methods, compositions, and kits for treatment of cancer |
| IL319255A (en) * | 2017-08-07 | 2025-04-01 | Univ Johns Hopkins | Methods and materials for cancer assessment and treatment |
| MA47408B1 (fr) * | 2017-12-20 | 2023-08-31 | Janssen Pharmaceutica Nv | Traitement du cancer |
-
2020
- 2020-05-29 US US17/613,652 patent/US20220233537A1/en not_active Abandoned
- 2020-05-29 SG SG11202112932QA patent/SG11202112932QA/en unknown
- 2020-05-29 MX MX2021014524A patent/MX2021014524A/es unknown
- 2020-05-29 AU AU2020282816A patent/AU2020282816A1/en not_active Abandoned
- 2020-05-29 EP EP20815357.7A patent/EP3976833A4/en active Pending
- 2020-05-29 KR KR1020217043300A patent/KR20220088830A/ko active Pending
- 2020-05-29 JP JP2021570824A patent/JP2022534118A/ja active Pending
- 2020-05-29 CN CN202080053765.5A patent/CN114207151A/zh active Pending
- 2020-05-29 CA CA3141871A patent/CA3141871A1/en active Pending
- 2020-05-29 WO PCT/US2020/035140 patent/WO2020243442A1/en not_active Ceased
- 2020-05-29 PH PH1/2021/552973A patent/PH12021552973A1/en unknown
-
2021
- 2021-11-25 IL IL288408A patent/IL288408A/en unknown